Observational registry to assess the longer-term risk of serious infections and malignancies reported with TNFα-blocker therapy, as well as the longer-term risk of cardiovascular and thromboembolic events in adult rheumatoid arthritis (RA) patients treated with Cimzia® as compared to non-biologic DMARD-treated controls.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01095393?cond=%22Arthritis%22&lup_s=07/28/2011&lup_d=30
